date:Apr 25, 2013
he three months to end-March were always going to be tough, due to a difficult comparison with a year earlier when GSK booked revenue from over-the-counter products and an incontinence drug that have since been sold.
GSK is expecting better times ahead as its pipeline starts to deliver - and it reiterated its 2013 expectations for sales growth, at constant exchange rates, of around 1 percent and core EPS growth of 3-4 percent.
Witty is banking on a number of new drugs to revive its fortunes in